; Whereas the United States Government has played a leading role in the recent progress made toward reducing the global burden of malaria and other infectious diseases, particularly through bilateral, multilateral, international, and civil society partners; Whereas, since 1893, the Walter Reed Army Institute of Research (WRAIR) has played a leadership role protecting United States servicemembers from the world’s most pervasive infectious diseases, including malaria, HIV/AIDS, Ebola, and dengue; Whereas WRAIR Center for Infectious Disease Research has been responsible for developing critical Food and Drug Administration-approved medicines, vaccines, drugs, and other interventions used to prevent malaria, Japanese encephalitis, hepatitis A, adenovirus, and other infectious diseases in deployed servicemembers; Whereas the WRAIR Malaria Vaccine and Experimental Therapeutics Branches have emerged as the Department of Defense’s premier effort to develop vaccines and drugs to protect the warfighter from malaria and other infectious diseases and military health threats; Whereas WRAIR continues to play a leadership role in the research and development of lifesaving medicines including the recently approved tafenoquine, a radical cure and prophylaxis that protects the warfighter from P vivax relapse, a condition that causes approximately 8.5 million clinical infections per year worldwide; Whereas WRAIR leads the fight against drug-resistant strains of malaria, developing new treatments that have revolutionized malaria prevention efforts; Whereas WRAIR’s international network of laboratories supports medical diplomacy and fosters United States-host nation collaborations in biomedical research; and Whereas WRAIR’s unique expertise, capabilities, and resources have led to historic clinical trials, testing vaccines to prevent the spread of HIV/AIDS, zika, and malaria: Now, therefore, be it